One infusion, two targets: a uric-acid-lowering drug takes aim at heart and kidney disease in youth-onset diabetes

NCT ID NCT03899883

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This pilot trial tests whether a single infusion of pegloticase, a drug that breaks down uric acid, can improve markers of heart and kidney health in young men aged 18–25 with youth-onset type 2 diabetes. High uric acid is common in this group and linked to later complications. The study measures blood pressure, artery stiffness, kidney blood flow, and other indicators one week after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a single infusion of pegloticase (Krystexxa), a drug that breaks down uric acid
What this could lead to
If it works, this could point toward a new way to protect the heart and kidneys in young people with type 2 diabetes.
What could go wrong
This is a very small pilot study with only 10 participants and a single dose, so results may not apply broadly. The drug can cause allergic reactions and is not yet tested in this age group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital Colorado

    Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.